Wall Street analyst estimates for Keros Therapeutics, Inc. (KROS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.96 | ||
| 2026-08-03 | $-1.45 | $-1.34 | -8.2% |
| 2026-05-14 | $-1.21 | $-0.92 | -31.5% |
| 2026-03-04 | $-0.86 | $-0.49 | -75.5% |
| 2025-11-05 | $-0.18 | $-1.11 | +83.8% |
| 2025-08-06 | $-0.76 | $-1.14 | +33.3% |
| 2025-05-06 | $3.62 | $-0.01 | +36300.0% |
| 2025-02-26 | $-1.14 | $-1.36 | +16.2% |
Valuation Ratios
| Price / Book | 0.81 |
| EV / EBITDA | -1.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $10.0M | 0 | $20.1M | 0 | $151000 | $3.5M | $244.1M |
| Cost of Revenue | $10.1M | $17.3M | $605000 | 0 | 0 | 0 | 0 | $1.5M |
| Gross Profit | -$111000 | -$7.3M | -$605000 | $20.1M | 0 | $151000 | $3.5M | $242.6M |
| Research & Development | $10.1M | $17.4M | $33.9M | $55.1M | $87.3M | $135.3M | $173.6M | $129.6M |
| Selling, General & Admin | $1.6M | $3.2M | $12.2M | $21.3M | $27.5M | $34.8M | $40.8M | $46.8M |
| Operating Expenses | $11.3M | $20.0M | $46.1M | $76.5M | $114.8M | $170.1M | $214.4M | $171.9M |
| Operating Income | -$1.7M | -$10.6M | -$46.7M | -$56.4M | -$114.8M | -$169.9M | -$210.8M | $70.6M |
| EBITDA | -$774000 | -$11.9M | -$44.9M | -$56.4M | -$104.0M | -$152.2M | -$185.8M | $93.4M |
| Interest Expense | 0 | $8000 | $6000 | $4000 | $1000 | 0 | 0 | 0 |
| Pre-tax Income | -$1.1M | -$12.3M | -$45.5M | -$56.7M | -$104.7M | -$153.0M | -$187.1M | $91.9M |
| Income Tax | $257000 | 0 | -$172000 | $2.0M | 0 | 0 | $300000 | $4.9M |
| Net Income | -$1.3M | -$12.3M | -$45.4M | -$58.7M | -$104.7M | -$153.0M | -$187.4M | $87.0M |
| EPS | $-0.15 | $-1.39 | $-2.93 | $-2.52 | $-4.15 | $-5.20 | $-5.00 | $2.34 |
| EPS (Diluted) | $-0.15 | $-1.39 | $-2.93 | $-2.52 | $-4.15 | $-5.20 | $-5.00 | $2.30 |
| Shares Outstanding (Diluted) | $8.9M | $8.9M | $15.5M | $23.3M | $25.2M | $29.4M | $37.4M | $37.9M |
Price
| Price | $10.74 |
| Market Cap | $344M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABSI · CRVS · CTMX · MLTX · NAGE · OLMA · RGNX
Explore sector: Healthcare · Biotechnology
More sections of KROS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks